Butterfly Network (BFLY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.01
- Estimate
- -$0.04
- Surprise
- +72.7%
- Revenue (period 2026-06-30)
- $32.6M
- Score at report (before → after)
- 4.9 → 5.0/10
Revenue source: xbrl.
How the report landed
Butterfly Network (BFLY) reported a narrower loss than forecast — diluted EPS of -$0.01 against the -$0.04 estimate (a 72.7% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Sell (4.9/10) to Hold at 5.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BFLY Sell at 5.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +72.7% surprise compares with a +47.1% four-quarter average. Next scheduled report: 2026-10-30.
What supports the rating
- Strong earnings beat streak (4/4)
- Strong growth profile
What argues against it
- Concentration risk — Supplier: TSMC
- Concentration risk — Supplier: Benchmark
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.55
- Price target
- $9.85
- Stop
- $8.88
- Upside to target
- +3.1%
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
BFLY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.54B
- P/E (fwd)
- -159.2
- 52-week range
- $1.39–$10.05
- Off 52-week high
- 5.0%
- RSI (14)
- 66
- Volume vs avg
- 0.87×
- Score today
- 5.4/10